Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 20 | -0.73 Increased by +35.96% | -2.58 Increased by +71.71% |
| May 6, 20 | -0.83 Increased by +55.38% | -2.04 Increased by +59.31% |
| Feb 18, 20 | -0.77 Increased by +57.22% | -0.99 Increased by +22.22% |
| Nov 6, 19 | -0.76 Increased by +61.62% | -1.30 Increased by +41.54% |
| Aug 1, 19 | -1.14 Increased by +57.78% | -1.86 Increased by +38.71% |
| May 8, 19 | -1.86 Increased by +48.33% | -1.98 Increased by +6.06% |
| Feb 27, 19 | -1.80 Increased by +70.59% | -2.52 Increased by +28.57% |
| Nov 14, 18 | -1.98 Increased by +85.69% | -3.42 Increased by +42.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -958.00 K Increased by +68.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -896.00 K Increased by +72.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -800.00 K Increased by +85.90% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.11 M Increased by +55.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -3.08 M Increased by +36.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -3.27 M Increased by +20.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -5.67 M Decreased by -10.67% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -4.71 M Decreased by -136.66% | Decreased by N/A% Decreased by N/A% |
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.